Show simple item record

dc.contributor.authorAbu Zaid, Men_US
dc.contributor.authorDinh, PCen_US
dc.contributor.authorMonahan, POen_US
dc.contributor.authorFung, Cen_US
dc.contributor.authorEl-Charif, Oen_US
dc.contributor.authorFeldman, DRen_US
dc.contributor.authorHamilton, RJen_US
dc.contributor.authorVaughn, DJen_US
dc.contributor.authorBeard, CJen_US
dc.contributor.authorCook, Ren_US
dc.contributor.authorAlthouse, Sen_US
dc.contributor.authorArdeshir-Rouhani-Fard, Sen_US
dc.contributor.authorSesso, HDen_US
dc.contributor.authorHuddart, Ren_US
dc.contributor.authorMushiroda, Ten_US
dc.contributor.authorKubo, Men_US
dc.contributor.authorDolan, MEen_US
dc.contributor.authorEinhorn, LHen_US
dc.contributor.authorFossa, SDen_US
dc.contributor.authorTravis, LBen_US
dc.contributor.authorPlatinum Study Groupen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2019-06-24T09:41:21Z
dc.date.issued2019-05-01en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/31085753en_US
dc.identifierjnccn18157en_US
dc.identifier.citationJ Natl Compr Canc Netw, 2019, 17 (5), pp. 459 - 468en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3274
dc.identifier.eissn1540-1413en_US
dc.identifier.doi10.6004/jnccn.2018.7109en_US
dc.description.abstractBACKGROUND: This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern platinum-based chemotherapy. PATIENTS AND METHODS: Eligible TCS were <55 years of age at diagnosis and treated with first-line platinum-based chemotherapy. Participants underwent physical examinations and completed questionnaires regarding 15 AHOs and health behaviors. Hypogonadism was defined as serum testosterone levels ≤3.0 ng/mL or use of testosterone replacement therapy. We investigated the role of 2 single nucleotide polymorphisms (rs6258 and rs12150660) in the sex hormone-binding globulin (SHBG) locus implicated in increased hypogonadism risk in the general population. RESULTS: Of 491 TCS (median age at assessment, 38.2 years; range, 18.7-68.4 years), 38.5% had hypogonadism. Multivariable binary logistic regression analysis identified hypogonadism risk factors, including age at clinical evaluation (odds ratio [OR], 1.42 per 10-year increase; P= .006) and body mass index of 25 to <30 kg/m2 (OR, 2.08; P= .011) or ≥30 kg/m2 (OR, 2.36; P= .005) compared with <25 kg/m2. TCS with ≥2 risk alleles for the SHBG SNPs had a marginally significant increased hypogonadism risk (OR, 1.45; P= .09). Vigorous-intensity physical activity appeared protective (OR, 0.66; P= .07). Type of cisplatin-based chemotherapy regimen and socioeconomic factors did not correlate with hypogonadism. Compared with TCS without hypogonadism, those with hypogonadism were more likely to report ≥2 AHOs (65% vs 51%; P= .003), to take medications for hypercholesterolemia (20.1% vs 6.0%; P<.001) or hypertension (18.5% vs 10.6%; P= .013), and to report erectile dysfunction (19.6% vs 11.9%; P= .018) or peripheral neuropathy (30.7% vs 22.5%; P= .041). A marginally significant trend for increased use of prescription medications for either diabetes (5.8% vs 2.6%; P= .07) or anxiety/depression (14.8% vs 9.3%; P= .06) was observed. CONCLUSIONS: At a relatively young median age, more than one-third of TCS have hypogonadism, which is significantly associated with increased cardiovascular disease risk factors, and erectile dysfunction. Providers should screen TCS for hypogonadism and treat symptomatic patients.en_US
dc.format.extent459 - 468en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.titleAdverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-11-21en_US
rioxxterms.versionofrecord10.6004/jnccn.2018.7109en_US
rioxxterms.licenseref.startdate2019-05-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJ Natl Compr Canc Netwen_US
pubs.issue5en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublisheden_US
pubs.volume17en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHuddart, Roberten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record